MyChesCo on MSN1h
Lungpacer Medical Secures FDA Approval for AHRF Trial
Lungpacer Medical has announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device ...
Managed Healthcare Executive12h
FDA Approves First Generics of Xarelto
Two companies have received approved for a generic of the 2.5 mg tablet of anticoagulant rivaroxaban, which is used to reduce ...
CNET on MSN5d
Natural Medicine vs. FDA Drugs: Which Should You Use for Your Ailment?
FDA-approved drugs are also often patented and subject to various laws regarding exclusivity for a given manufacturer. At the ...
Anti-Aging Pill for Dogs Certified as 'Effective' by FDA. But Could It Work for Humans, Too?
A new anti-aging pill for dogs, created by biotech company Loyal, was certified by the FDA as having a 'reasonable ...
Male enhancement capsules recalled for undeclared ingredients, FDA announces
One Source Nutrition, Inc. is voluntarily recalling all of its Vitality male enhancement capsules nationwide after an FDA ...
American Council on Science and Health2d
The FDA Finally Removes a Huge Barrier to an Effective Schizophrenia Medicine
For 35 years, the FDA has placed onerous restrictions on the only drug it has ever approved for treatment-resistant ...
FDA nominee sidesteps questions on abortion pill, agency layoffs and other issues
Dr. Marty Makary is largely sidestepping Senate questions about his plans to lead the Food and Drug Administration ...
Healio10h
FDA grants fast track designation to X-linked retinoschisis treatment
The FDA granted fast track designation to ATSN-201 for the treatment of X-linked retinoschisis, according to a press release from Atsena Therapeutics.
Medscape6d
As Trump Administration Probes Long-Approved Medications, Could FDA Revoke Approvals?
A new federal commission will ‘investigate’ decades-old mental health as well as weight loss drugs, prompting concerns from ...
Managed Healthcare Executive2d
FDA Approves First Biosimilar of Xolair
Celltrion’s Omlyclo is interchangeable with Xolair to treat the same conditions: asthma, chronic rhinosinusitis, food allergy ...
Ophthalmology Times1d
FDA accepts new drug application for low-dose atropine from Sydnexis
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.